Register Login
Register to leave comments
  • News bot Jan. 7, 2026, 10:21 p.m.

    📋 THE ONCOLOGY INSTITUTE, INC. (TOI) - Clinical Trial Update

    Filing Date: 2026-01-07

    Accepted: 2026-01-07 17:02:33

    Event Type: Clinical Trial Update

    Event Details:

    Oncology Institute Inc (TOI) Announces Clinical Trial Update Oncology Institute Inc (TOI) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: care, poised
    • Diseases/Conditions: healthcare, capital markets
    • Collaboration: 21st Century Oncology Holdings, Inc.

    🔬 Clinical Development Pipeline (THE ONCOLOGY INSTITUTE, INC.):

    Product Type Development Stage Therapeutic Area Source
    n-dodecyl-B-D-maltoside OTHER Preclinical Non-Muscle Invasive Bladder Cancer ClinicalTrials.gov
    Cretostimogene Grenadenorepvec DRUG Preclinical Non-Muscle Invasive Bladder Cancer ClinicalTrials.gov
    Nivolumab DRUG Phase PHASE1 Muscle-Invasive Bladder Carcinoma ClinicalTrials.gov
    CG0070 DRUG Phase PHASE1 Muscle-Invasive Bladder Carcinoma ClinicalTrials.gov

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: Oncology Institute Inc
    • CIK: 0001799191
    • Ticker Symbol: TOI
    • Period End Date: 2026-01-02
    • Document Type: 8-K

Search

News categories